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The study was aimed at evaluating oxaliplatin/doxorubicin combination therapy in recurrent ovarian cancer.
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Pegylated liposomal doxorubicin (PLD) has been effective in recurrent ovarian cancer, but the ideal treatment
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Bevacizumab use has dramatically increased in solid tumors. This retrospective cohort study evaluated the
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We analyzed the effect of the N factor on prognosis of T3C ovarian cancer patients who underwent
optimal surgery (OpS). According to the analyses of N factor in OpS group, prognosis was poor in N1
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